The Drug Enforcement Administration (DEA) has delayed its hearing on the potential rescheduling of marijuana until 2025, pushing back decisions that could impact cannabis regulation nationwide. Currently classified as a Schedule I substance alongside heroin and LSD, marijuana’s status severely restricts medical research and patient access, despite mounting evidence of its therapeutic benefits.
The DEA cites the need for thorough review and expert input as reasons for the delay. Advocates, however, express frustration, noting how prolonged prohibition affects millions who could benefit from medical cannabis. For researchers, rescheduling could open new avenues for funding and study, while for patients, it could bring more consistent access and acceptance across states.
This site Ganja.nu provided a public comment earlier this year on the rescheduling issue. This comment remains registered and documented by the federal government.